Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of methylphenidate hydrochloride extended-release tablets, which are primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [1] Company Summary - The drug utilizes advanced three-layer osmotic pump controlled release technology [1] - The approval aligns with the 2023 consensus on the diagnosis and treatment of adult ADHD in China, which indicates an adult ADHD prevalence rate of approximately 3% [1] - Long-acting methylphenidate extended-release formulations have been recommended as the first-line treatment for adult ADHD patients [1] Industry Summary - According to the 2020 consensus on early identification, standardized diagnosis, and treatment of ADHD in children, the prevalence rate of ADHD among children in China is as high as 6.26% [1] - Methylphenidate formulations have become the first-line standard treatment for children with ADHD aged 6 and above [1] - Sales data from the Drug Intelligence Database indicates that the sales revenue in domestic sample hospitals was approximately 350 million RMB in 2023, with further growth to about 430 million RMB in the first three quarters of 2024 [1]